Lawmakers are negotiating a short-term deal to fund the Department of Homeland Security, aiming to avoid a partial government shutdown this weekend. The talks occur against the backdrop of heightened political pressure following recent violence in Minneapolis and a shift in the administration's enforcement rhetoric.
In a fiery address to the U.S. Conference of Mayors, Minneapolis Mayor Jacob Frey called on local leaders nationwide to resist what he described as aggressive federal immigration enforcement, arguing such operations undermine public safety and constitutional rights.
In a late-night social media post, former President Donald Trump threatened to impose a 50% tariff on all Canadian aircraft sold in the U.S. and decertify new planes, citing Canada's alleged refusal to certify Gulfstream jets. The move, targeting Bombardier, risks disrupting U.S. regional aviation and corporate travel.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
After a brutal 2025, fast-casual restaurant stocks are rallying sharply in early 2026. Analysts debate whether this marks a genuine recovery or a temporary bounce, as consumers pivot towards grocery and convenience store meals, forcing a reckoning on value and quality.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.
Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.
Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.
ResMed Inc. reports an 11% revenue surge for its second fiscal quarter, driven by robust mask sales and strategic acquisitions, while navigating competitive pressures and capitalizing on emerging healthcare trends.
Defense contractor L3Harris Technologies capped off a record 2025 with surging orders and a strategic pivot, announcing plans to take its high-growth Missile Solutions unit public in 2026 while securing a novel $1 billion investment from the Department of War to accelerate production.
Amid corporate restructuring fears, a professional with a substantial nest egg but no home equity grapples with the daunting math of early retirement, soaring healthcare costs, and an uncertain housing market.
Shares and bonds of New World Development surged after reports that Blackstone is in advanced talks to become its largest shareholder, a potential lifeline for the embattled Hong Kong property giant and a signal of shifting sentiment in the city's real estate market.
GSK makes a dual strategic move, acquiring RAPT Therapeutics for its food allergy portfolio and securing broader European approval for its RSV vaccine Arexvy, reinforcing its focus on immunology and respiratory health.
Amid renewed threats of steep US tariffs, South Korean officials are scrambling to salvage a key trade deal, with high-level talks in Washington failing to yield an immediate breakthrough.
Cardinal Health (CAH) stock has drawn renewed investor interest following robust financial results, with revenue topping $234 billion and net income near $1.6 billion. The healthcare distributor's shares have rallied over 66% in the past year, though its premium valuation compared to peers is sparking debate among analysts.
Regeneron Pharmaceuticals' shares have softened in recent weeks, lagging behind broader market gains. A deep dive into valuation metrics, including DCF analysis and P/E ratios, suggests the biotech giant may be significantly undervalued. We examine the numbers behind the headlines and what they mean for investors.
In a landmark move, Venezuela's parliament has passed reforms to its hydrocarbons law, easing state control and aiming to lure back foreign capital to its struggling oil industry, coinciding with a partial easing of U.S. sanctions.
Once a symbol of tech retrenchment, San Francisco's Showplace Square is undergoing a profound transformation. Major leases by AI firms Together AI and Physical Intelligence, coupled with Vanderbilt University's planned campus, are redefining the neighborhood as a nexus for technology, education, and innovation, offering a significant boost to the city's office recovery narrative.
SanDisk's Q2 2026 earnings reveal a 31% sequential revenue surge to $3 billion, driven by AI infrastructure build-out. The company highlights a fundamental industry shift towards long-term agreements as data center demand, now the largest NAND market, reshapes commercial dynamics.
